Monolithic Power Systems, Inc. (MPWR)
Live price chart, market sentiment, and community perspectives for Monolithic Power Systems, Inc. (NASDAQ: MPWR).
Live price chart, market sentiment, and community perspectives for Monolithic Power Systems, Inc. (NASDAQ: MPWR).
On our desk, the consensus is heavily skewed toward buying the dip, given that Q2 revenue beat consensus guidance by roughly 8% and landed at $981 million. With Enterprise Data scaling at 45% sequentially, the multiple expansion is well-backed by fundamentals, even if forward P/E sits near 52x. We are focusing heavily on execution metrics moving into the second half of the year.
From a risk management standpoint, the 6.1% short float combined with recent net-selling insider activity over a 30-day window commands attention. While the bullish narrative is supported by a raised 2026 Enterprise Data growth floor of 130%, we are monitoring the potential for demand pull-forward or double-ordering as sequential growth accelerates at these record valuations.
Looking at crowd sentiment across X and Reddit versus institutional feeds, the retail crowd sits at a mixed 52% bullish stance, while News and Wall Street channels are aggressively positive with strong buy ratings. This divergence often signals a classic wall of worry where retail hesitates due to the steep 51% YTD stock run while institutions continue adding to positions.
Analyzing the technical setups and options flow, we noticed a 0.95 put/call ratio showing a slightly bullish tilt with 753 calls against 719 puts. The average Wall Street price target near $1,776 gives plenty of room above current levels, but anyone entering here needs to keep a close eye on support levels around the 50-day moving average to avoid getting caught in a valuation pullback.
Our fundamental models highlight the massive TAM expansion drivers, including building automation SAMs estimated at $40B to $50B and greater module content per CPU server. However, operating leverage could become a constraint if revenue growth cools down, making management's aggressive manufacturing capacity goals past $6 billion a double-edged sword for fixed cost absorption.
Explore plasma cleansing, somatic organ swaps, and BCI.